These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31081725)

  • 1. Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study.
    Gao L; Xiang X; Zhang C; Gao L; Yang T; Wang S; Li B; Lou S; Yi Su ; Liu Y; Zhang X
    Hematology; 2019 Dec; 24(1):225-231. PubMed ID: 31081725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
    Grisariu S; Shapira MY; Or R; Avni B
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
    Noring K; Carlsten M; Sonnevi K; Wahlin BE
    BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
    Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
    Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity.
    Yeral M; Aytan P; Gungor B; Boga C; Unal A; Koc Y; Kaynar L; Buyukkurt N; Eser B; Ozdoğu H
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):652-660. PubMed ID: 32605899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
    Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
    Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
    Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
    Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
    Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS
    Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
    Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.
    Martínez C; Salamero O; Arenillas L; Duque J; López-Guillermo A; Rovira M; Urbano-Ispízua A; Fernández-Avilés F; Carreras E; Montserrat E
    Leuk Lymphoma; 2007 Oct; 48(10):1968-75. PubMed ID: 17917965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
    Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B
    Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma.
    Mocikova H; Pytlik R; Markova J; Steinerova K; Kral Z; Belada D; Trnkova M; Trneny M; Koza V; Mayer J; Zak P; Kozak T
    Leuk Lymphoma; 2011 Sep; 52(9):1668-74. PubMed ID: 21699377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
    Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
    Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03).
    Wirth A; Prince HM; Roos D; Gibson J; O'Brien P; Zannino D; Khodr B; Stone JM; Davis S; Hertzberg M
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1158-1166. PubMed ID: 30553941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.
    Maeng CH; Ko YH; Lim DH; Kang ES; Choi JY; Kim WS; Kim SJ
    Cancer Res Treat; 2017 Jan; 49(1):92-103. PubMed ID: 27188204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.